Aurinia Pharmaceuticals to Participate in H.C. Wainwright 23rd Annual Global Investment Conference

Rhea-AI Summary

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) will present at the H.C. Wainwright & Co. 23rd Annual Global Investment Conference from September 13-15, 2021. The presentation will be available on-demand starting September 13, 2021, at 3 PM ET. Interested parties can access it via the Aurinia corporate website. The company specializes in biopharmaceuticals, particularly focusing on therapies for serious diseases with high unmet medical needs, and has recently launched the first FDA-approved oral treatment for adult lupus nephritis.

VICTORIA, British Columbia--(BUSINESS WIRE)-- Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (the “Company”) today announced that members of the senior management team will participate in the H.C. Wainwright & Co. 23rd Annual Global Investment Conference, September 13-15, 2021. The Aurinia presentation will be available on-demand beginning September 13, 2021 at 3 pm ET.

The audio webcast is available here. Interested parties can also register and access the presentation under "News/Events” through the “Investors” section of the Aurinia corporate website at www.auriniapharma.com. A replay of the webcast will be available on Aurinia’s website.

ABOUT AURINIA

Aurinia is a fully integrated biopharmaceutical company focused on delivering therapies to treat targeted patient populations that are impacted by serious diseases with a high unmet medical need. The Company recently introduced the first FDA-approved oral therapy indicated for the treatment of adult patients with active lupus nephritis (LN). Aurinia’s head office is in Victoria, British Columbia; its U.S. commercial hub is in Rockville, Maryland; and the Company focuses development efforts globally.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210910005494/en/

Investor and Corporate Contact:

Dana Lynch, Corporate Communications & IR

dlynch@auriniapharma.com

Source: Aurinia Pharmaceuticals Inc.

FAQ

When will Aurinia Pharmaceuticals present at the Global Investment Conference?

Aurinia Pharmaceuticals will present at the H.C. Wainwright & Co. 23rd Annual Global Investment Conference from September 13-15, 2021.

How can I access Aurinia's presentation at the conference?

The presentation will be available on-demand starting September 13, 2021, at 3 PM ET, accessible via the Aurinia corporate website.

What is Aurinia Pharmaceuticals known for?

Aurinia Pharmaceuticals is known for its biopharmaceuticals, particularly for launching the first FDA-approved oral therapy for adult lupus nephritis.

What is the stock symbol for Aurinia Pharmaceuticals?

The stock symbol for Aurinia Pharmaceuticals is AUPH.

Where is Aurinia Pharmaceuticals headquartered?

Aurinia Pharmaceuticals is headquartered in Victoria, British Columbia.